The $6.5 billion raised by biopharmaceutical companies in the first quarter of 2025 is down nearly 20% year over year, according to a report from GlobalData. The firm says investors continue to favor later-stage companies with clinical data.
The FDA asked Cytokinetics for the Risk Evaluation and Mitigation Strategy after it had already accepted the application for aficamten, a potential competitor to Bristol Myers Squibbs heart drug Camzyos. Analysts say this development could signal a change in FDA thinking about risk management for the broader drug class.
Discover what tools are essential for efficient, safe surgical extractions in today’s health care landscape, from elevators to forceps and beyond.
Johnson & Johnson’s Imaavy is now FDA-approved for treating generalized myasthenia gravis, introducing competition to Argenx and UCB drugs that treat this rare neuromuscular disorder. J&J is also developing its new drug for other diseases and projects it could reach $5 billion in peak sales across multiple rare and prevalent conditions.
Regulus Therapeutics drug farabursen is a potential first-in-class treatment for a rare kidney disease whose only FDA-approved therapy introduces severe toxicity risks. Farabursen is joining a Novartis drug lineup spanning several therapies for rare renal disorders.
AIQ is not just about adopting a new technology. We’re talking about a fundamentally different way of thinking. A shift in what’s possible in clinical research, and a new standard for execution.
A federal court judge ruling leaves in place an FDA determination that shortages of the Novo Nordisk drugs Wegovy and Ozempic are resolved. Consequently, compounding pharmacies must stop making their versions of the metabolic medicines or face FDA enforcement action.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Caribou Biosciences’ restructuring narrows the biotech’s focus to two off-the-shelf cell therapies for blood cancers, whose key data readouts have been pushed out to the second half of 2025. It’s the CRISPR-editing company’s second cash-saving restructuring in the past year.
Ben Zeskind, co-founder, president and CEO of Immuneering, is attempting a new approach to treat certain types of cancers. If it works, there will be a vast improvement in the quality of life of cancer patients.
By prioritizing sustainability-minded and compliant waste management in the workplace, healthcare leaders can advance patient and employee well-being, as well as environmental and fiscally responsible programs.
Bristol Myers Squibb’s Cobenfy failed to outdistance a placebo in a Phase 3 test that evaluated the drug as an adjunct to antipsychotics in schizophrenia patients. Last September, the FDA approved Cobenfy as a standalone schizophrenia treatment.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
A greater weight must be placed on vaccine manufacturing and distribution, both in the United States and worldwide, as we saw major imbalances in the world's response to Covid-19 that highlighted gaps in accessibility.
Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are important because many patients do not live long enough to receive a second-line cancer therapy.
The FDA approved Sanofi and Regeneron Pharmaceuticals drug Dupixent as a treatment for the inflammatory skin disorder chronic spontaneous urticaria. The regulatory decision comes two years after the agency turned down an application for the biologic drug in this indication.
Robert F. Kennedy Jr.’s rise to become secretary of the Department of Health and Human Services has some concerned that anti-vaccine policies are coming. If the nation’s top public health agency pulls support of vaccination, other healthcare stakeholders will need to step up to fill the vaccine messaging void.
The Trump administration aims to change the Medicare Drug Price Negotiation Program in a way that would delay when certain drugs can be selected for negotiation.